1. Home
  2. DSP vs IKT Comparison

DSP vs IKT Comparison

Compare DSP & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

N/A

Current Price

$10.15

Market Cap

272.1M

Sector

Technology

ML Signal

N/A

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

SELL

Current Price

$1.30

Market Cap

209.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
DSP
IKT
Founded
1999
2008
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
272.1M
209.3M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DSP
IKT
Price
$10.15
$1.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
9
Target Price
★ $19.32
$5.55
AVG Volume (30 Days)
418.3K
★ 515.3K
Earning Date
11-09-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 157.14
57.76
EPS
★ N/A
N/A
Revenue
★ $344,201,000.00
N/A
Revenue This Year
$26.56
N/A
Revenue Next Year
$20.92
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 19.00
N/A
52 Week Low
$8.72
$1.29
52 Week High
$14.80
$2.61

Technical Indicators

Market Signals
Indicator
DSP
IKT
Relative Strength Index (RSI) 32.55 33.23
Support Level $9.75 N/A
Resistance Level $12.45 $1.71
Average True Range (ATR) 0.84 0.12
MACD -0.26 -0.01
Stochastic Oscillator 1.15 2.25

Price Performance

Historical Comparison
DSP
IKT

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: